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ABSTRACT.  
 
Background. The cortactin (CTTN) gene has been found, by transcriptomic profiling, 
to be overexpressed in pediatric osteosarcoma. The location of CTTN at 11q13 and the 
role of cortactin in cytoskeleton restructuring make CTTN of interest as a potential 
biomarker for osteosarcoma. 
Materials and methods. Osteoblasts were isolated from 20 high-grade osteosarcomas 
before chemotherapy, and paired with cell samples from normal tissue, prior to RNA 
expression analysis on HG-U133A chips (Affymetrix). Semiquantitative CTTN mRNA 
expression was analyzed by real-time PCR. An osteosarcoma tissue microarray (TMA) 
containing 233 tissue spots from 48 patients was used for an immunohistochemical 
(IHC) study of cortactin. 
Results. Transcriptomic profiling and real-time PCR analysis indicated increased 
CTTN expression in osteosarcomas (p = 0.001, Student’s T test). TMA IHC showed 
cortactin to be present more frequently and in greater abundance in osteosarcomas than 
non-tumoral osteoblastic samples (p < 0.006, Mann-Withney test). Analysis of clinical 
outcomes indicated that overall survival for patients with primary tumors positive for 
cortactin was significantly lower than that for patients with cortactin negative (or only 
weakly staining) tumors (p = 0.0278, Log-rank test). 
Conclusions. Our preliminary data support the hypothesis that over-expression of 
cortactin, contained in the 11q13 amplicon, is involved in osteosarcoma carcinogenesis. 
The potential of cortactin overexpression as a biomarker for osteosarcoma is 
consolidated. 
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1. INTRODUCTION 
 
Osteosarcoma is the most common primary malignant tumor of bone, characterized by 
production of malignant osteoid and a high propensity to metastasize [1]. It most 
frequently occurs in the second decade of life. Several factors have been related to 
survival, including the presence of metastatic disease and the histologic response to 
preoperative treatment [2,3]. Despite efforts in new therapeutic modalities based on 
neoadjuvant chemotherapy followed by surgical resection and postoperative 
chemotherapy, overall survival rates rarely exceed 60–65% [2]. 
  
We have previously reported the transcriptomic profiling [4] of pediatric osteosarcoma 
based on a paired analysis of tumoral and normal cell lines derived from high-grade 
conventional osteosarcomas. This approach enabled assessment of the changes 
associated with oncogenesis and determination of molecular alterations influencing 
differential clinical behaviour and/or response to treatment. We found a robust 
clustering that revealed a novel subset of genes associated with the carcinogenesis of 
pediatric osteosarcoma, in which the transcription factor EBF2 was found to be highly 
expressed in tumor samples. 
 
In the study reported here, CTTN was one of the most significant genes overexpressedin 
osteosarcomas. The product of the CTTN gene (previously known as EMS1) is 
cortactin, an actin filament-binding protein and target of various kinases, which has 
emerged as a central element connecting signalling pathways with cytoskeleton 
restructuring. Remodelling of the actin cytoskeleton has effects on cell migration, 
motility, and adhesion, as well as on tumor invasion and metastasis [5]. Here we report 
the identification and validation of cortactin (and overexpression of CTTN) as a 
potential new marker for poor outcome in osteosarcoma. 
 
A large body of evidence implicates cortactin in the pathogenesis of human neoplasia. 
Most frequently, CTTN overexpression occurs through chromosomal amplification of 
the 11q13.3 region [6], a genetic event that has been described in osteosarcoma [7]. In 
addition to cortactin, a number of other genes potentially involved in carcinogenesis are 
present in the 11q13 amplicon, including the CCDN1 gene, which encodes cyclin D1. 
CTTN and cyclin D1 have been considered the most likely promotors of tumor 
aggressiveness since, unlike many of the other genes in the amplicon, they are 
consistently overexpressed upon amplification [6]. 
 
 
 
2. MATERIALS AND METHODS 
 
2.1. Patients and clinical samples 
 
Primary tumor samples were obtained by needle biopsy from 20 high-grade 
osteosarcomas before induction chemotherapy, and paired-normal osteoblasts were 
isolated when patients underwent surgery (Table 1). All patients were treated at the 
Pediatric Oncology Unit of the University Clinic of Navarra. All samples were obtained 
with written informed consent from patients and/or their parents, and the protocol was 
approved by the local ethics committee (CEIC-CUN). Human osteoblasts were isolated 
and characterized according to procedures we have published previously [4, 8]. Normal 
osteoblastic cells were passaged 1 to 5 times, whereas tumoral cells were passaged 
between 20 and 40 times; in all cases, cells were 90% confluent and in logarithmic 
growth phase prior to molecular analysis. 
 
Cell lines were designated by the number of the patient followed by B (biopsy, i.e. 
tumor-derived lines) or N (normal, i.e. paired normal cell lines). 
  
 
2.2. RNA extraction for microarray analysis. 
 
RNA was isolated, labelled and hybridized on HGU133A chips (Affymetrix) by 
Progenika Biopharma as previously described [4]. The test set comprised 14 samples: 
osteosarcoma cell lines and the paired osteoblastic control cell lines derived from 7 
patients (numbers 473, 475, 486, 491, 500, 524 and 531 in Table 1). 
 
 
2.3. Gene expression validation by real-time PCR 
 
To validate CTTN gene expression results, we performed real-time PCR assay by 
means of TaqMan Micro Fluidic Cards on the tumour-derived cells from patients 554, 
588, 595, 598, 605, 628, 631, 636, 648, 652, 661, 664 and 669 (Table 1). Total RNA 
was isolated from confluent cultures using Trizol RNA (2 µg). After treatment with 
DNase I, RNA was reverse transcribed using SuperScript II reverse transcriptase and 
random primers. 
 
Semiquantitative analysis of CTTN mRNA expression in the tumour samples was 
carried out by real-time polymerase chain reaction (RT-PCR) with the ABI PRISM 
7300 Sequence Detector and the software Sequence Detector version 1.4 (Perkin-
Elmer/Applied Biosystems, Foster City, California). The semiquantitative CTTN 
mRNA level was expressed as a percentage relative to that of glyceraldehyde-3-
phosphate dehydrogenase mRNA (GAPDH), which was determined with TaqMan 
assays (Hs00193322_ml, Applied Biosystems). Relative levels of expression were 
determined by the 2−ΔΔCt method, and every assay was performed in triplicate. 
 
 
2.4. Immunohistochemistry 
 
An osteosarcoma tissue microarray (TMA) containing 233 tissue spots derived from 48 
patients was developed in our institution using samples from our archives. Tissues in 
the microarray included normal bone (17.2%), osteosarcomas at diagnosis (26.3%) and 
after induction with chemotherapy (11.1%), relapsed tumors (10.1%), and metastatic 
tumors (35.4%). Tissue sections were formalin-fixed and paraffin-embedded. Paraffin 
was removed from the tissues and the sections were hydrated through a graded series of 
ethanol solutions. Endogenous peroxidase activity was quenched with 3% hydrogen 
peroxidase for 10 min. Microwave antigen retrieval was carried out with EDTA (0.5 
mmol/L, pH 8) for 2 × 15 min. Nonspecific binding sites were blocked with 5% goat 
normal serum in TBS-Tween 20 (with DAKO washing buffer) for 30 min. Sections 
were incubated with anti-cortactin antibody (#ab81208, Abcam, Cambridge, UK) 
overnight at 4◦C. The working dilution was 1:300. After rinsing with TBS, sections 
were incubated with polyclonal Envision complex (DAKO). Peroxidase activity was 
shown by 3,3’-diaminobenzidine. Finally, sections were washed in water, lightly 
counterstained with hematoxylin, dehydrated, and mounted in DPX. 
 
For the TMA, a semiquantification procedure was performed according to a score that 
took into account the extension and intensity of the immunoreactivitysignal. The “0” 
score was assigned when the sample was negative (i.e. less than 10% of the cells were 
positive). Score “1” indicates a weak signal; Score “2”, a strong and widespread signal; 
and Score “3”, an intense and extensive [9]. 
 
 
2.5. Statistical analysis 
 
Because this study was designed as a confirmatory analysis focused on specific genes 
that were previously shown to have statistically significant expression changes in our 
set of osteosarcomas, multiple test correction was not applicable. Gene expression 
levels were compared with the Mann-Whitney U test or the Kruskal-Wallis test. 
Differences in survival were plotted in Kaplan-Meier curves and were tested for 
statistical significance with the Log-rank test (Mantel Cox correlation). The statistical 
analysis was done with the SPSS (Statistical Package for the Social Sciences, version 
15.0) software. We used p < 0.05 as criterion of statistical significance. 
 
 
 
3. RESULTS 
 
The application of transcriptomic profiling and stringent bioinformatic processing to a 
set of 7 tumourderived in vitro cultures from chemonaive osteosarcoma samples paired 
with 7 normal osteoblastic cell populations identified CTTN as one of several genes 
differentially upregulated (p = 0.038) in the osteosarcoma samples. Real-time PCR 
assay with Micro Fluidic Cards validated this finding (p = 0.003). Expression levels in 
tumoral tissues was additionally tested by real-time PCR in an independent subset of 13 
tumourderived and 12 normal osteoblastic cell lines derived from primary tissues; there 
was a significant increase of CTTN mRNA in tumors (p = 0.001, Student’s T test, Fig. 
1). 
 
On establishing the above result, and in view of the fact that previous studies have 
found both CTTN and CCND1 to be overexpressed in some tumours with the 11q13 
amplification, we retrospectively checked the expression of U133A GeneChip probesets 
208711_s at and 208712_at, both of which concern sequences located within the 
CCND1 gene. At the stringency of the statistical test used in the cDNA array analysis, 
there were no significant differences in the expression of these sequences. 
 
The immunohistochemical (IHC) analysis (based on a monoclonal antibody to cortactin 
that was used on a tissue microarray that included 48 osteosarcoma patients) showed 
significantly higher expression of cortactin in osteosarcoma tissue compared to non-
tumoral osteoblastic tissue from normal bone (p < 0.006, Mann-Withney test). We 
found a significantly higher number of positive cases, and the intensity of 
immunoreactivity was higher, in metastasis and relapse samples as compared with 
samples from primary tumors (p = 0.028, Kruskal-Wallis test) (Figs 2 and 3). Of 
samples from primary tumors and lung metastases, 25% were positive, and the pattern 
of staining was typically patchy and light. In cases of local recurrences and distant bone 
metastases, however, all samples were positive, and staining was generally uniform and 
dense. 
 
Analysis of outcomes after stratification of patients according to IHC scores indicated 
that overall survival for patients whose primary tumors were positive for cortactin (IHC 
scores higher than 2, n = 20) was significantly reduced relative to that for patients with 
weak cortactin staining (IHC scores lower or equal to 2, n = 8, p = 0.0278, Log-rank 
test, Fig. 4). The association between survival and the cortactin IHC was not maintained 
after correction for multiple testing, with only a tendency for association remaining 
(adjusted p-value = 0.101), probably due to the small sample size (n = 28). 
 
In conjunction, the results of the various areas of the study suggest an inverse 
relationship between patient survival and amounts of cortactin in tumor cells. 
 
 
 
3.1. DISCUSSION 
 
Cortactin has been described as an actin-associated scaffolding protein, which binds and 
activates the actinrelated protein 2/3 complex, and has emerged as a central element 
connecting signalling pathways with cytoskeleton restructuring [10,11]. Remodelling of 
the actin cytoskeleton has effects on cell migration, motility, and adhesion, as well as on 
tumor invasion and metastasis [5]. 
 
Cortactin is overexpressed in many types of human cancers, including head and neck 
and esophageal squamous carcinomas and colorectal, gastric, hepatocellular, breast and 
ovarian cancers [11,12]. 
 
The gene coding for cortactin is in the chromosome region 11q13 and is amplified in a 
wide variety of human cancers, but scarcely in osteosarcoma [13], suggesting that the 
11q13 amplicon may harbor key gene(s) involved in carcinogenesis regardless of tissue 
types [14]. Amplification of 11q13 is specific for certain malignancies and seems to 
occur at high frequency in some adult carcinomas (breast, head and neck, ovary, 
squamous cell carcinoma, melanoma and hepatocellular carcinoma). Within these 
patients, the amplification dentifies a subgroup of patients with poor prognosis (see [6] 
for a review). 
 
Several oncogenes and cancer-related genes, such as CCND1, FGF4, FGF3, CTTN, and 
PAK1, have been mapped to the 11q13 chromosome region. The amplification or 
involvement of these genes in osteosarcoma has not been reported so far. CCND1 and 
CTTN are coamplified, at the same level, in most adult carcinomas with 11q13 
amplification, which may indicate that both genes confer selective advantage to these 
tumors [6]. 
 
The relationship between cortactin expression, CTTN over-expression and the 
clinicopathological parameters of pediatric osteosarcoma remains largely unexplored. 
Our findings indicate that marked cortactin IHC positivity associates with poor survival. 
In some studies immunostaining for cyclin D1 was weak or absent in most tumor 
samples and cyclin D1 overexpression was not detected [15,16]. The implication is that 
the gene overexpressed in the 11q13 amplicon in osteosarcoma might be CTTN, at least 
in a subset of tumors. Also, it has been reported that there is overexpression of the genes 
in the amplified region without amplification, suggesting that there must be mechanisms 
other than amplification to activate the biologially important genes in that region. In the 
specific case of osteosarcoma, the alteration of the G1 phase of the cell cycle is a 
frequent event, by the abrogation of either the Rb1 or the TP53 pathways. Our data is 
congruent with reports that cyclin D1 is usually expressed at a low level in 
osteosarcoma, a finding that supports the idea of there being mechanisms other than 
amplification involved in activation of genes within the amplicon region [17]. 
 
As reported before, various studies have found an association between 11q13 
amplification and poor prognosis, including higher pathological stage, lymph node and 
distant metastasis, and decreased survival [18]. The consistent over-expression of 
CTTN in 11q13-amplified tumors along with its ubiquitous presence in cell motility 
structures, such as lamellipodia and invadopodia, have generated a great deal of interest 
in the role of cortactin in tumor invasion. 
 
On the basis of the localization and function of cortactin in non-transformed cell lines, it 
was suggested that over-expression of cortactin in human cancers might lead to 
increased cell migration [11,12]. Cell migration is required for many biological 
processes, and the aberrant regulation of cell migration drives progression of many 
diseases, including cancer invasion and metastasis. Therefore, understanding the 
fundamental mechanisms of cell migration is critical for our understanding of both basic 
biology and the pathology of disease [19]. In view of this model of cancer, we not only 
analyzed the expression of CTTN in paired normal and tumoral tissues and of cortactin 
in different stages of the disease (normal bones, primary osteosarcomas, metastases and 
local relapses) but also compared the IHC expression of cortactin in primary 
osteosarcoma tissues from metastatic and non-metastatic patients. As reported here, 
both analyses indicated that, also in osteosarcoma, cortactin could be associated with 
the development of metastatic disease and therefore reduced survival. 
 
In conclusion, our data suggest an involvement of the CTTN gene in the carcinogenesis 
of pediatric osteosarcoma, and that over-expression of this gene and the corresponding 
marked IHC positivity for the protein cortactin could be predictors of metastasis and 
reduced survival for pediatric patients with this tumor. Nevertheless, the number of 
cases analyzed in this paper does not warrant that our results be regarded without some 
degree of caution. In addition, further studies should be performed to confirm the 
specific mechanism/s by which CTTN and CCND1 are overexpressed and whether 
there are other genes within or in the proximity of the 11q13 amplicon that are also 
involved in osteosarcoma. 
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 Table 1. Clinical and histopathologic features of the osteosarcoma patients 
Patient Histology Age (yr) Gender Location Necrosis Follow-up Suvival (mo) 
473 Fibroblastic 15.08 M Tibia 95% Remission 96 
475 Osteoblastic 23.5 F Femur 100% Remission 96 
486 Osteochondroblastic 24 M Tibia 1NA Died of disease 14 
491 Osteochondroblastic 16.6 M Femur 90% Died of disease 84 
500 Osteoblastic 11 M Femur > 90% Remission 90 
524 Osteochondroblastic 11 F Femur < 10% Remission 90 
531 Osteochondroblastic 22 F Multifocal 85% Died of disease 27 
554 Telangiectasic 16 M Femur 90% Remission 108 
588 Osteochondroblastic 16 M Tibia 70% Died of disease 46 
595 Osteoblastic 16.66 F Femur 90% Died of disease 7 
598 Osteoblastic 14 F Femur NA Died of disease 7 
605 Osteoblastic 27.75 F Sacro-iliac NA Died of disease 3 
628 Osteoblastic 13.25 M Femur 95% Remission 47 
631 Osteoblastic 12.16 M Femur 100% Remission 45 
636 Osteoblastic 15 M Femur 99% Remission 45 
648 Osteoblastic 15.66 F Tibia 100% Remission 52 
652 Osteoblastic 10.75 M Tibia 100% Remission 36 
661 Osteoblastic 14.58 F Femur 95% Died of disease 7 
664 Chondroblastic 12 M Femur > 90% Remission 20 
669 Osteoblastic 16.5 M Femur 70% Died of disease 13 
1NA: not available. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Representation of CTTN relative expression in pediatric osteosarcoma tissues 
and normal bones by real-time PCR. 
 
 
 
 
 
Figure 2. Cytoplasmic staining of CTTN in a primary tumor (a) and a lung metastasis 
(b) compared to a normal bone (c), showing the typical different intensity of staining. 
The asterisk marks tumoral osteoid; the arrows indicate examples of stained tumoral 
osteoblasts. (IHC, 200x). 
 
 
 
Figure 3. Box plot representing the median CTTN score for the different osteosarcoma 
stages analyzed. On the Y axis an arbitrary scale represents the IHC score (see Materials 
and Methods section). 
 
 
 
 
 
 
 
Figure 4. Kaplan-Meier survival curves for primary osteosarcomas according to IHC 
cortactin expression.  
 
